Clinic Roundup

 Calimmune Inc., of Los Angeles, said the first patient started treatment in a Phase I/II trial testing gene medicine Cal-1. The study will enroll 12 HIV-positive patients who will be infused with their own T cells and stem cells that have been modified to block the HIV receptor CCR5 and prevent HIV fusion.